Skip to main content
Equibles
PRPO logo

PRPO · Precipio, Inc. · Metrics

Track PRPO — free

Use PRPO with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PRPO.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$20.61 -0.64 (-3.01%) At close · Oct 22
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Notwithstanding the aforementioned circumstances, there remains substantial doubt about the Company's ability to continue as a going concern for the next twelve months from the date these condensed consolidated financial statements were issued. There can be no assurance that the Company will be able to successfully achieve its initiatives summarized above in order to continue as a going concern over the next twelve months from the date of issuance of this Quarterly Report on Form 10-Q.”
View the 10-Q filed Aug 14, 2026
Market Cap
$36.90M
Shares
1.79M
Volume · Oct 22 27.61K Avg daily vol (3M) 112.7K

PRPO metrics

90 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$20.61
Market cap
$36.90M

Price action

20 metrics
Price change (1W)
-8.6%
Price change (30D)
-21.5%
Price change (3M)
-9.9%
Price change (6M)
-23.8%
Price change (YTD)
-10.3%
Price change (1Y)
-2.2%
Trailing year
Price change (5Y)
—
52-week high
$32.37
52-week low
$19.33
Change from 52-week high
-36.3%
Change from 52-week low
+6.6%
Annualized volatility
60.9%
Annualized volatility (3M)
53.4%
Beta
0.4
RSI (14D)
30.2
Price vs SMA 50
-18.7%
Price vs SMA 200
-18.1%
Avg volume (3M)
112,698
Relative volume
0.2
Average dollar volume
$2.88M

Company

3 metrics
Sector
Healthcare
Industry
Diagnostics & Research
Shares outstanding
1.79M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
1.3×
reciprocal yield 77.1%
EV / EBITDA
—
EV / EBIT
—
P / sales
1.4×
reciprocal yield 71.5%
P / book
2.6
reciprocal yield 38.8%
FCF yield
2.1%
TTM · current market cap
Buyback yield
—
P / FCF
48.2
reciprocal yield 2.1%
P / operating cash flow
34.6
reciprocal yield 2.9%
Earnings yield
-3.2%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
0.9×
reciprocal yield 107.5%
EV / revenue historical average (5Y)
1.3×
reciprocal yield 74.1%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-17

Profitability

9 metrics
Gross margin
44.1%
Operating margin
-5.7%
Trailing 12 months
Net margin
-4.5%
Gross profit (TTM)
$12.00M
Operating profit (TTM)
−$1.55M
Net income (TTM)
−$1.22M
Trailing 12 months
Diluted EPS (TTM)
$-0.62
FCF margin
2.9%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$15.82
Gross profit per diluted share (TTM)
$6.99
Operating profit per diluted share (TTM)
$-0.85
EBITDA per diluted share (TTM)
$-0.16
Net income per diluted share (TTM)
$-0.67
Operating cash flow per diluted share (TTM)
$0.63
Free cash flow per diluted share (TTM)
$0.45
Capital expenditures per diluted share (TTM)
$0.18
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
$1.19
Book value per share
$8.18

Growth

11 metrics
Revenue growth YoY
+24.2%
Year over year
Net income growth YoY
-395.9%
Revenue (TTM)
$27.20M
Trailing 12 months
EPS growth YoY
-340.0%
Shares change YoY
+11.5%
Year over year · more shares
Revenue CAGR (3Y)
+36.7%
Revenue CAGR (5Y)
+31.6%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-8.2%
Return on assets
-5.7%
Debt / equity
0.0
Current ratio
1.8
EBITDA (TTM)
−$360,000
Free cash flow (TTM)
$789,000
Quick ratio
1.6
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$2.75M
Latest balance sheet
Cash & equivalents
$3.08M
Total assets
$21.32M
Total debt
$325,000

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$1.10M
Capital expenditures (TTM)
$311,000
R&D (TTM)
−$136,000
SG&A (TTM)
$9.62M
Stock compensation (TTM)
$2.10M
R&D / revenue
—
Stock compensation / revenue
7.7%

Ownership (13F)

9 metrics
13F filers
18
13F filer change QoQ
+3
Institutional ownership
8.8%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
2.7%
Private-fund adviser ownership
2.2%
Active holders' share change QoQ
-28.7%
Holder tenure
6.3
Price vs estimated holder cost
-34.7%

Ownership (registered funds)

1 metrics
Index-fund ownership
3.8%

Short interest

3 metrics
Short interest
3.8%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
44 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1043961 CUSIP 74019L602 13F (30d) 1 filings 1 filers Visit website Investor relations